BfArM, the German Federal Institute for Drugs and Medical Devices has confirmed acceptance of the IND application of Oneness Biotech for Phase 3 trial of diabetic foot ulcer new drug, ON101 (protocol#ON101CLCT04).
BfArM, the German Federal Institute for Drugs and Medical Devices has confirmed acceptance of the IND application of Oneness Biotech for Phase 3 trial of diabetic foot ulcer new drug, ON101 (protocol#ON101CLCT04).
建議您使用以下瀏覽器觀看合一網站,
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?